Investigations into the mixed muscle–secretory phenotype of cardiomyocytes from the atrial
appendages of the heart led to the discovery that these cells produce, in a regulated …

Natriuretic peptide [NP; B‐type NP (BNP), N‐terminal proBNP (NT‐proBNP), and
midregional proANP (MR‐proANP)] concentrations are quantitative plasma biomarkers for …

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …

A organização de uma diretriz clínica é tarefa complexa, que necessariamente deve
envolver planejamento prévio, coordenação apropriada, revisão aprofundada da literatura …

Hypertension Canada provides annually updated, evidence-based guidelines for the
diagnosis, assessment, prevention, and treatment of hypertension in adults and children …

Aims To assess tolerability and optimal time point for initiation of sacubitril/valsartan in
patients stabilised after acute heart failure (AHF). Methods and results TRANSITION was a …

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …

РЕКОМЕНДАЦИИ, СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ, ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ
НЕДОСТАТОЧНОСТЬ, ОСТРАЯ ДЕКОМПЕНСАЦИЯ СЕРДЕЧНОЙ …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …

Importance Compared with enalapril, sacubitril-valsartan reduces cardiovascular mortality
and heart failure hospitalization in patients with heart failure and reduced ejection fraction …